Approaching Profitability
The company reported being close to breakeven with an adjusted EBITDA loss of $124,000, improving from a loss of over $6 million per quarter in Q2 2022.
International Sales Growth
International sales contributed over 40% of total revenues, with significant growth in markets like Germany and Australia.
Strong Balance Sheet
The company ended the quarter with $16 million in cash and plans to sell underutilized assets, potentially generating an additional $4-5 million.
High Gross Margin
Gross profit for Q2 was 33%, which is the highest in over four years, driven by increased international medical cannabis revenue.
Expansion in Germany
Sales to German pharma partner STADA increased by 35% compared to the first half of 2023, with significant growth in oil and flower units.